Latest News

Split-face trial finds 34-gauge low-dead-space injector makes upper-face Botox injections hurt less, bruise less, and waste fewer units.

FDA clears RHA Redensity Eye for undereye hollows, offering soft, stretchable HA filler with 12-month results and strong safety data in a 52-week study.

Learn how private equity rollups reshape dermatology—EBITDA deals, MSOs, and the real tradeoffs for owners, PAs, and new grads.

Shanna Miranti, MPAS, PA-C, explores how fertility treatments can affect skin and hair, including acne, melasma, and hair loss, and offers guidance for patient care.

Meta-analysis suggests vitiligo links to lower skin cancer rates, with significantly reduced squamous cell carcinoma; phototherapy shows higher estimates but remains inconclusive.

Phase 3 data from Merck and Moderna show mRNA vaccine intismeran plus pembrolizumab cuts melanoma relapse and spread after surgery, hinting at new adjuvant standard.

Preclinical data show GX-03 reduced IL-31 by nearly 68% and dermatitis severity by 66% in a murine model of atopic dermatitis.

New research shows dermatologists continue to back daily sunscreen to prevent aging and skin cancer, debunking viral myths and spotlighting safer new filters coming to the US.

Joan Levy, PhD, chief science officer at the Melanoma Research Alliance, discussed the significance of Tudriqev's accelerated approval for patients with anti-PD-1-refractory melanoma.

This review of the latest dermatological studies includes insights on brodalumab for plaque psoriasis, physiological characteristics of scalps with high sebum production, disease burden of anogenital PsO, and more.

Judson Brewer, MD, PhD, discussed how the trigger-behavior-result habit loop model can be applied to itch-scratch cycles in atopic dermatitis.

GBD 2021 shows urticaria burden in the Middle East and North Africa has stayed flat for 3 decades, but rates vary widely based on location, gender, age, and more.

LEO Pharma will acquire worldwide rights to dersimelagon, an investigational oral therapy under FDA review for EPP and XLP.